Your body releases more insulin when you eat sugar than when the same amount of sugar is dripped straight into a vein, even when blood sugar ends up identical.1PubMed. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans That gap is the incretin effect, and it means the gut is part of blood-sugar control, sending the pancreas a “food is coming” signal before sugar levels peak. In type 2 diabetes that signal is weakened, and repairing it is the idea behind some of today’s best-known diabetes and weight-loss drugs.2PubMed. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
The Two Gut Hormones Behind the Effect
The signal is carried by two gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).3PubMed. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions Special sensing cells in the gut lining release GLP-1 when they detect sugar, protein fragments and fats from a meal.4PubMed Central. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell? Sugar and protein trigger these cells through an electrical change, while fats act through different sensors on the cell surface, depending on the fat’s size.5PubMed Central. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell? In healthy people, these hormones account for roughly 70% of the insulin released after drinking sugar.6PubMed. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
The two hormones come from different places. GLP-1 is made by sensing cells found mostly in the lower small intestine and the colon, while GIP is made by cells higher up in the small intestine. Those GIP cells sit closer to the stomach, so food reaches them sooner, which helps explain why GIP rises soon after eating; GLP-1 also rises quickly, even though most of its cells sit farther down. Each is released in proportion to what the meal contains, so a large meal with plenty of sugar and fat produces a bigger rise than a snack.
The head start exists because insulin takes time to act. The gut senses food minutes before sugar fully reaches the blood, and starting insulin early prevents a big spike after meals.
The “glucose-dependent” in GIP’s name matters for you. The hormone boosts insulin only when blood sugar is raised, and when sugar is normal or low the push fades. This built-in brake is why these hormones alone rarely cause dangerous lows.
Gut bacteria may feed into the same system. When they ferment fiber, they make small fatty acids. In animal gut tissue, these fatty acids nudge the lower gut’s cells to release more GLP-1.7PubMed Central. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR28PubMed. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon That has been shown in animal tissue, though, not yet as a dependable effect of eating fiber in people.
How the Hormones Control Blood Sugar
Both hormones latch onto their own receptors on the pancreas’s insulin-making cells.9PubMed. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation This raises an internal signal in those cells that turns up insulin release, but only when blood sugar is high.10PubMed. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation That’s a key difference from some older diabetes pills, which force the pancreas to release insulin whatever your blood sugar is doing. GLP-1 also helps those cells burn sugar faster, giving them more energy to release insulin.11PubMed Central. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
The two hormones pull glucagon in opposite directions. Glucagon is the pancreas hormone that tells the liver to release sugar. GLP-1 holds glucagon down when blood sugar is above normal fasting levels.12PubMed Central. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review GIP raises glucagon, mainly when blood sugar is low.13PubMed Central. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review Together they lower sugar after meals while guarding against lows.
Put in order, a meal goes like this: food reaches the gut and the hormones are released. They travel to the pancreas, where insulin rises faster than sugar alone would cause. Glucagon falls, so the liver stops adding sugar. Then an enzyme called DPP-4, found on cells throughout the body, breaks both hormones down almost immediately.14American Health & Drug Benefits. Incretin Impairment: The Role of GLP-1 and DPP-4 in Type 2 Diabetes Management15PubMed. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP That clears the signal once the meal is processed, and it means natural GLP-1 lasts only about 1 to 2 minutes in the blood.16PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
That short life is a problem for medicine, since natural GLP-1 can’t be given as a drug. So drugmakers took one of two routes: build longer-lasting copies, or block DPP-4.
What Happens to the Incretin Effect in Type 2 Diabetes
A reduced incretin effect is a consistent finding in people with type 2 diabetes.17PubMed Central. Incretin hormones and type 2 diabetes The gut’s share of insulin release fell from about 73% in people without diabetes to about 36% in people with it.18PubMed. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Yet GIP levels in the blood were not lower in people with diabetes.19PubMed. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes The problem is less about making the hormones and more about the response to them.
The gut still releases the hormones. The weakness lies in how well the pancreas answers. When given GLP-1, people with type 2 diabetes produced about 70% of the insulin response of healthy people.20PubMed Central. Incretin hormones and type 2 diabetes With GIP, the response was only about 40%.21PubMed Central. Incretin hormones and type 2 diabetes The pancreas still listens to GLP-1, so the most likely reason the overall effect weakens is the lost GIP response.22PubMed. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions The effect is reduced rather than gone, since a partial response remains, especially to GLP-1.
There’s a second problem with GIP. In type 2 diabetes, it can push glucagon up after meals, adding to high blood sugar.23PubMed. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes A weakened gut-to-pancreas signal is a separate problem from insulin resistance, and it adds to the blood-sugar spikes after meals.
This finding shaped treatment. Since the pancreas still answers GLP-1, boosting GLP-1 was the logical fix, which is why GLP-1 drugs came before GIP-based ones. Giving more of the hormone can partly make up for a weaker response.
How Ozempic-Type Drugs and DPP-4 Pills Use the Effect
Medicines use two strategies to beat the 2-minute problem. The first is the GLP-1 receptor agonist, such as liraglutide and exenatide. These resist DPP-4 and supply much higher than natural GLP-1 levels.24PubMed Central. Long-Acting Glucagon-Like Peptide 1 Receptor Agonists The second is the DPP-4 inhibitor, such as sitagliptin, vildagliptin and saxagliptin. These slow the breakdown of your own GLP-1, keeping it at natural levels.25PubMed Central. Long-Acting Glucagon-Like Peptide 1 Receptor Agonists Blocking DPP-4 also preserves your own GIP.26PubMed Central. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Semaglutide (Ozempic, Wegovy) is 94% the same as natural GLP-1 but tweaked to resist DPP-4.27PubMed Central. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials It binds a carrier protein in the blood and lasts about 7 days, allowing one shot a week.28PubMed Central. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
GLP-1 drugs lower blood sugar more and cause more weight loss than sitagliptin, likely because of their higher hormone levels.29PubMed Central. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? The natural levels from DPP-4 pills mostly steer blood sugar, while the much higher levels from GLP-1 drugs reach appetite and stomach effects too. DPP-4 pills, on the other hand, are easy to add after metformin, usually don’t change weight, and cause few stomach side effects.30PubMed Central. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Ask your doctor which matters more for you, a bigger effect or fewer side effects.
You can often tell the kind you’re on from the name. Names ending in -glutide or -natide are usually GLP-1 drugs, mostly injections, and names ending in -gliptin are DPP-4 pills. Form alone doesn’t settle it, though, because semaglutide also comes as a daily tablet.
Most GLP-1 drugs are injected under the skin, daily or weekly, because these hormone-like molecules would otherwise be digested in the stomach. DPP-4 pills are small molecules that survive digestion, so they’re taken by mouth, usually once a day. If you’re unsure which you take, check the generic name on the label or pharmacy bag rather than the brand name.
Why GLP-1 Also Curbs Appetite
GLP-1 receptors sit in the brain and in the nerves of the gut, not just the pancreas.31PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery Activating them slows how quickly the stomach empties.32PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery The nerve running from the gut to the brain is needed for this slowing.33The Journal of Clinical Investigation. GLP-1 physiology and pharmacology along the gut-brain axis GLP-1 also acts on appetite centers in the brain to create a feeling of fullness.34PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
Day to day, this can mean feeling full after smaller portions and less interest in snacking between meals. Rich or large meals may sit heavily because the stomach empties slowly. These are the same effects that drive weight loss.
Because food stays in the stomach longer on these drugs, they can matter before surgery or procedures that need an empty stomach.35PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery Tell the care team you take a GLP-1 drug before any procedure with anesthesia.
Mounjaro and the Newer Dual and Triple Drugs
Giving GLP-1 and GIP together raises insulin and lowers glucagon more than either alone.36PubMed Central. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials So tirzepatide (Mounjaro, Zepbound) was built as one molecule that activates both receptors.37PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists In a large trial it lowered average blood sugar and weight more than semaglutide in people with type 2 diabetes.38PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists It was approved for type 2 diabetes in 2022 and for obesity in 2023.39PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists Its design starts from a GIP-like molecule altered so that it also acts on GLP-1 receptors and lasts about a week, so one weekly injection delivers both signals.
It may seem odd to add GIP when diabetes blunts its effect. But the drugs give far above natural levels, and alongside GLP-1 the two act together more strongly. GIP may also soften some GLP-1 side effects, an idea still being studied.
Retatrutide, still in development, activates GLP-1, GIP and glucagon receptors.40PubMed Central. Retatrutide—A Game Changer in Obesity Pharmacotherapy It has produced large weight loss and better blood sugar in studies.41PubMed Central. Retatrutide—A Game Changer in Obesity Pharmacotherapy
Nausea and Other Side Effects, and How Long They Last
The slowed stomach emptying and fullness signals that help with appetite also cause side effects, from mild upset to rare serious problems like stomach paralysis and pancreatitis.42PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations The common ones are nausea, diarrhea, vomiting and constipation.43PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP About 6 to 10% of people stop treatment and about 15% lower their dose because of them.44PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
The picture usually improves. Side effects are strongest at the start and ease over the first 90 days.45PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP On weekly semaglutide for weight loss, nausea rose from about 5% to 15% during the 13-week dose increase, then fell to about 8%.46PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP Raising the dose slowly lets the body adapt over weeks to months.47PubMed Central. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis So follow the prescribed step-up schedule rather than jumping ahead.
Going straight to a high dose tends to bring more nausea and vomiting. The goal is a dose that works while keeping side effects tolerable, and not everyone needs the top dose.
To get through the early weeks, eat smaller meals and stop when full. Go easy on greasy or very large meals, and stay hydrated, especially if you have vomiting or diarrhea. If symptoms are hard, ask about pausing a dose increase.
Some symptoms are more than normal upset. Severe, lasting belly pain that may spread to the back needs urgent care. Repeated vomiting that stops you keeping fluids down calls for a call to your doctor. Both can signal pancreatitis or severe stomach slowing.
Effects on the Heart, Liver and Kidneys
Large trials show several GLP-1 drugs reduce heart attacks, strokes, heart failure and heart-related deaths.48PubMed. Cardiovascular Risk Reduction With GLP-1 RA Drugs GLP-1 signaling improves blood vessel lining, lowers inflammation, and helps heart metabolism.49PubMed. Cardiovascular Risk Reduction With GLP-1 RA Drugs These drugs may also slow artery plaque buildup.50PubMed. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
The trials showing this were mainly in people with type 2 diabetes who already had heart disease or high heart risk. Which drug is chosen can therefore depend on heart history, not only on blood sugar.
These drugs may also help lower the risk of fatty liver disease and treat it.51PubMed. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease GLP-1 makes the kidneys release more salt and water.52PubMed. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation That can add to dehydration when you have vomiting or diarrhea, so drinking enough fluids matters more on these drugs, and it’s worth mentioning any kidney problems to your doctor before starting.
In animal studies GLP-1 calms brain inflammation, raising hope for Parkinson’s, though this is not yet proven in people.53PubMed Central. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases Don’t start these drugs for unproven uses without a doctor.